Adaptive Biotechnologies Corp (ADPT)

$3.13

-0.17

(-5.15%)

Market is closed - opens 7 PM, 17 Jun 2024

Insights on Adaptive Biotechnologies Corp

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 45.78M → 41.87M (in $), with an average decrease of 8.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -69.44M → -47.50M (in $), with an average increase of 46.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 75.4% return, outperforming this stock by 139.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 237.0% return, outperforming this stock by 328.8%

Performance

  • $3.11
    $3.25
    $3.13
    downward going graph

    0.64%

    Downside

    Day's Volatility :4.3%

    Upside

    3.69%

    downward going graph
  • $2.28
    $8.81
    $3.13
    downward going graph

    27.16%

    Downside

    52 Weeks Volatility :74.12%

    Upside

    64.47%

    downward going graph

Returns

PeriodAdaptive Biotechnologies CorpSector (Health Care)Index (Russel 2000)
3 Months
-1.57%
0.4%
0.0%
6 Months
-33.55%
8.7%
0.0%
1 Year
-62.69%
10.3%
0.0%
3 Years
-91.75%
17.0%
-23.8%

Highlights

Market Capitalization
477.5M
Book Value
$1.87
Earnings Per Share (EPS)
-1.49
PEG Ratio
0.0
Wall Street Target Price
6.6
Profit Margin
-123.24%
Operating Margin TTM
-116.45%
Return On Assets TTM
-17.1%
Return On Equity TTM
-61.58%
Revenue TTM
174.5M
Revenue Per Share TTM
1.2
Quarterly Revenue Growth YOY
11.200000000000001%
Gross Profit TTM
-13.7M
EBITDA
-171.2M
Diluted Eps TTM
-1.49
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.3
EPS Estimate Next Year
-1.06
EPS Estimate Current Quarter
-0.34
EPS Estimate Next Quarter
-0.33

Analyst Recommendation

Buy
    78%Buy
    21%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Adaptive Biotechnologies Corp(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 110.86%

Current $3.13
Target $6.60

Company Financials

FY18Y/Y Change
Revenue
55.7M
↑ 44.77%
Net Income
-46.4M
↑ 8.44%
Net Profit Margin
-83.44%
↑ 27.96%
FY19Y/Y Change
Revenue
85.1M
↑ 52.83%
Net Income
-58.8M
↑ 26.64%
Net Profit Margin
-69.14%
↑ 14.3%
FY20Y/Y Change
Revenue
98.4M
↑ 15.65%
Net Income
-139.6M
↑ 137.39%
Net Profit Margin
-141.93%
↓ 72.79%
FY21Y/Y Change
Revenue
154.3M
↑ 56.88%
Net Income
-205.6M
↑ 47.25%
Net Profit Margin
-133.22%
↑ 8.71%
FY22Y/Y Change
Revenue
185.3M
↑ 20.06%
Net Income
-142.5M
↓ 30.71%
Net Profit Margin
-76.88%
↑ 56.34%
FY23Y/Y Change
Revenue
170.3M
↓ 8.11%
Net Income
-225.3M
↑ 58.11%
Net Profit Margin
-132.29%
↓ 55.41%
Q4 FY22Q/Q Change
Revenue
55.2M
↑ 15.4%
Net Income
-24.5M
↓ 45.71%
Net Profit Margin
-44.43%
↑ 50.01%
Q1 FY23Q/Q Change
Revenue
37.6M
↓ 31.8%
Net Income
-61.7M
↑ 151.76%
Net Profit Margin
-163.99%
↓ 119.56%
Q2 FY23Q/Q Change
Revenue
48.9M
↑ 29.96%
Net Income
-47.8M
↓ 22.56%
Net Profit Margin
-97.72%
↑ 66.27%
Q3 FY23Q/Q Change
Revenue
37.9M
↓ 22.5%
Net Income
-50.3M
↑ 5.21%
Net Profit Margin
-132.65%
↓ 34.93%
Q4 FY23Q/Q Change
Revenue
45.8M
↑ 20.74%
Net Income
-69.4M
↑ 38.05%
Net Profit Margin
-151.67%
↓ 19.02%
Q1 FY24Q/Q Change
Revenue
41.9M
↓ 8.54%
Net Income
-47.5M
↓ 31.59%
Net Profit Margin
-113.45%
↑ 38.22%
FY18Y/Y Change
Total Assets
332.7M
↓ 8.22%
Total Liabilities
590.8M
↑ 0.63%
FY19Y/Y Change
Total Assets
912.3M
↑ 174.22%
Total Liabilities
341.3M
↓ 42.24%
FY20Y/Y Change
Total Assets
1.1B
↑ 22.37%
Total Liabilities
373.1M
↑ 9.34%
FY21Y/Y Change
Total Assets
923.3M
↓ 17.29%
Total Liabilities
319.2M
↓ 14.45%
FY22Y/Y Change
Total Assets
856.6M
↓ 7.23%
Total Liabilities
392.5M
↑ 22.95%
FY23Y/Y Change
Total Assets
661.1M
↓ 22.82%
Total Liabilities
352.9M
↓ 10.1%
Q4 FY22Q/Q Change
Total Assets
856.6M
↓ 3.12%
Total Liabilities
392.5M
↓ 0.98%
Q1 FY23Q/Q Change
Total Assets
791.5M
↓ 7.61%
Total Liabilities
367.5M
↓ 6.37%
Q2 FY23Q/Q Change
Total Assets
764.5M
↓ 3.4%
Total Liabilities
368.6M
↑ 0.29%
Q3 FY23Q/Q Change
Total Assets
717.7M
↓ 6.13%
Total Liabilities
356.0M
↓ 3.4%
Q4 FY23Q/Q Change
Total Assets
661.1M
↓ 7.88%
Total Liabilities
352.9M
↓ 0.9%
Q1 FY24Q/Q Change
Total Assets
620.3M
↓ 6.17%
Total Liabilities
345.6M
↓ 2.07%
FY18Y/Y Change
Operating Cash Flow
-32.3M
↓ 7.46%
Investing Cash Flow
736.0K
↓ 97.98%
Financing Cash Flow
1.2M
↓ 97.51%
FY19Y/Y Change
Operating Cash Flow
205.4M
↓ 736.73%
Investing Cash Flow
-481.7M
↓ 65547.96%
Financing Cash Flow
319.9M
↑ 25534.29%
FY20Y/Y Change
Operating Cash Flow
-149.7M
↓ 172.87%
Investing Cash Flow
-117.0M
↓ 75.7%
Financing Cash Flow
293.6M
↓ 8.23%
FY21Y/Y Change
Operating Cash Flow
-192.7M
↑ 28.76%
Investing Cash Flow
181.2M
↓ 254.82%
Financing Cash Flow
27.1M
↓ 90.75%
FY22Y/Y Change
Operating Cash Flow
-183.9M
↓ 4.56%
Investing Cash Flow
2.9M
↓ 98.4%
Financing Cash Flow
132.3M
↑ 387.24%
Q4 FY22Q/Q Change
Operating Cash Flow
-30.0M
↓ 29.21%
Investing Cash Flow
-97.5M
↓ 268.14%
Financing Cash Flow
6.0K
↓ 100.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-59.2M
↑ 97.05%
Investing Cash Flow
63.0M
↓ 164.56%
Financing Cash Flow
672.0K
↑ 11100.0%

Technicals Summary

Sell

Neutral

Buy

Adaptive Biotechnologies Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp
-15.86%
-33.55%
-62.69%
-91.75%
-92.23%
Moderna, Inc.
Moderna, Inc.
5.54%
63.93%
8.78%
-29.22%
787.95%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
7.08%
21.82%
32.37%
97.97%
233.31%
Novo Nordisk A/s
Novo Nordisk A/s
7.11%
43.97%
76.7%
240.79%
458.71%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
9.1%
18.8%
38.18%
156.4%
176.63%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp
NA
NA
0.0
-1.3
-0.62
-0.17
NA
1.87
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.71
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.32
30.32
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.73
49.73
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.07
31.07
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp
Buy
$477.5M
-92.23%
NA
-123.24%
Moderna, Inc.
Moderna, Inc.
Buy
$55.7B
787.95%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$113.1B
233.31%
30.32
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$634.9B
458.71%
49.73
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$123.6B
176.63%
31.07
39.46%

Institutional Holdings

  • Viking Global Investors LP

    20.35%
  • Vanguard Group Inc

    8.73%
  • Matrix Capital Management Company, LLC

    7.85%
  • BlackRock Inc

    7.59%
  • ARK Investment Management LLC

    7.17%
  • Rubric Capital Management LP

    7.13%

Company Information

we are a commercial-stage, biotechnology organization located in the hot biotech locations of seattle, washington and south san francisco, ca. our world class scientists have invented a patent-pending technology that combines advances in high-throughput sequencing with state-of-the-art computer infrastructure to provide an in-depth analysis of the t- and b-cell repertoire, a specific and important part of the immune system. this information is driving the r&d community to support the fights against cancer, auto-immune disease, and much, much more. we're often asked to describe our company culture. it is very easy ... we're a hard working group of top-notch individuals who are passionate about wanting to make a difference in the world. we know our employees are our most valuable asset, and every employee’s contribution is appreciated. open communication and collaboration are always encouraged in every interaction throughout the organization. we have high expectations of ourselves, and

Organization
Adaptive Biotechnologies Corp
Employees
709
CEO
Mr. Chad M. Robins M.B.A.
Industry
Commercial Services

FAQs